Showing results (2611-2620 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|December 13, 2021
Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European CountriesSiu Hing Lo, Claire Lawrence, Yasmina Martí, et al.
Pharmacoeconomics|December 16, 2021
Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic EvaluationsSónia Romano, Débora Figueira, Inês Teixeira, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Pharmacoeconomics|November 6, 2022
Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5LMona Aghdaee, Yuanyuan Gu, Kompal Sinha, et al.
Pharmacoeconomics|April 7, 2019
Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care TimeScott D Grosse, Jamison Pike, Rieza Soelaeman, et al.
Pharmacoeconomics|October 20, 2022
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment ArrangementAmy Gye, Stephen Goodall, Richard De Abreu Lourenco
Pharmacoeconomics|September 19, 2022
Value Set for the EQ-5D-Y-3L in HungaryFanni Rencz, Gábor Ruzsa, Alex Bató, et al.
Pharmacoeconomics|May 7, 2011
Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disordersMarieke Krol, Jocé Papenburg, Marc Koopmanschap, et al.
Pharmacoeconomics|July 8, 2011
US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness researchPeter J Neumann, Pei-Jung Lin, Tom E Hughes
Pharmacoeconomics|June 11, 2011
Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidencePetros Pechlivanoglou, Robin De Vries, Simon M G J Daenen, et al.
Pageof 336